Oncotarget is a peer-reviewed, open-access biomedical journal dedicated to publishing high-quality, primarily oncology-focused research.

On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Visit https://www.oncotarget.com/

Oncotarget

Oncotarget published this editorial on June 19, 2023 in Volume 14, entitled, “The hope for targeting fatty acid binding proteins in multiple myeloma" by Heather Fairfield and Michaela R. Reagan from the Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, ME; Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME; Tufts University School of Medicine, Boston, MA.

DOI - https://doi.org/10.18632/oncotarget.28437

Correspondence to - Michaela R. Reagan - Michaela.Reagan@mainehealth.org

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28437

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, multiple myeloma, FABPs, fatty acid binding proteins, immunoncology, pre-clinical discovery

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

The Hope for Targeting Fatty Acid Binding Proteins in Multiple Myeloma | Oncotarget

Oncotarget published this trending editorial on September 15, 2023 in Volume 14, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma" by Kuniko Horie and Satoshi Inoue from the Division of Systems Medicine and Gene Therapy, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Tokyo, Japan.

DOI - https://doi.org/10.18632/oncotarget.28463

Correspondence to - Satoshi Inoue -  sinoue07@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28463

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, renal cell carcinoma (RCC), tyrosine kinase inhibitor (TKI), Dipeptidyl peptidase IV (DPP4), drug resistance, drug repurposing

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Repurposing DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma | Oncotarget

Oncotarget published this trending research paper on September 15, 2023 in Volume 14, entitled, “Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma" by researchers from the Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL.

DOI - https://doi.org/10.18632/oncotarget.28508

Correspondence to - Jason B. Fleming - jason.fleming@moffitt.org

Abstract

Background: Patient-derived organoids (PDOs) and xenografts (PDXs) have been extensively studied for drug-screening. However, their usage is limited due to lengthy establishment time, high engraftment failure rates and different tumor microenvironment from original tumors. To overcome the limitations, we developed real time-live tissue sensitivity assay (RT-LTSA) using fresh tumor samples.

Methods: Tissue slices from resected pancreatic cancer samples were placed in 96-well plates, and the slices were treated with chemotherapeutic agents. The correlation between the chemo-sensitivity of tissue slices and each patient’s clinical outcome was analyzed.

Results: The viability and tumor microenvironment of the tissue slices are well-preserved over 5 days. The drug sensitivity assay results are available within 5 days after tissue collection. While all 4 patients who received RT-LTSA sensitive adjuvant regimens did not develop recurrence, 7 of 8 patients who received resistant adjuvant regimens developed recurrence. We observed significantly improved disease-free survival in the patients who received RT-LTSA sensitive adjuvant regimens (median: not reached versus 10.6 months, P = 0.02) compared with the patient who received resistant regimens. A significant negative correlation between RT-LTSA value and relapse-free survival was observed (Somer’s D: −0.58; P = 0.016).

Conclusions: RT-LTSA which maintains the tumor microenvironment and architecture as found in patients may reflect clinical outcome and could be used as a personalized strategy for pancreatic adenocarcinoma. Further, studies are warranted to verify the findings.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28508

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, pancreatic cancer, sensitivity assay, chemotherapy

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Real Time Ex Vivo Chemosensitivity Assay for Pancreatic Adenocarcinoma | Oncotarget

Oncotarget published this trending editorial on July 7, 2023 in Volume 14, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?" by researchers from Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, NJ.

DOI - https://doi.org/10.18632/oncotarget.28435

Correspondence to - Marta Vaz Batista - marta.vaz@hff.min-saude.pt

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28435

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, brain metastasis, HER2+ breast cancer

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer | Oncotarget

Oncotarget published this editorial on May 26, 2023 in Volume 14, entitled, “Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer” by Mira Al Jaberi, Wolfgang Clough and Samir Dalia from the Department of Medical Oncology, Mercy Hospital, Joplin, MO.

DOI - https://doi.org/10.18632/oncotarget.28419

Correspondence to - Samir Dalia - samir.dalia@mercy.net

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28419

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, non small cell lung cancer, MET mutation, targeted therapy, precision medicine

About Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Updates on MET Targeted Therapy for EXON 14 Mutations in Lung Cancer | Oncotarget

Oncotarget published this trending editorial on August 30, 2023 in Volume 14, entitled, “Predicting the molecular functions of regulatory genetic variants associated with cancer" by Jun S. Song and Mohith Manjunath from Department of Physics, University of Illinois at Urbana-Champaign, Urbana, IL; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL; Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL.

DOI - https://doi.org/10.18632/oncotarget.28451

Correspondence to - Jun S. Song - songj@illinois.edu

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28451

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, genome-wide association studies, cancer risk, regulatory variants, functional genomics

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.